Cocaine

Dose and frequency are the dominant variables. A single low-dose exposure typically clears the SAMHSA 150 ng/mL urinary cutoff within 24 to 48 hours, while repeated high-dose binge use can extend urinary BE detection to seven days or more. Cumulative exposure does not produce a true tissue reservoir the way THC does, but chronic users metabolize and excrete BE over a longer tail simply because the dosing interval has been short relative to the elimination half-life. The most aggressive published case reports describe positive BE results out to two weeks after the last exposure in chronic heavy users, but the typical window for occasional use is much shorter.

Route of administration affects pharmacokinetics. Insufflated powder cocaine reaches peak plasma levels in roughly 30 to 60 minutes and produces a relatively gradual decline. Smoked crack cocaine reaches peak plasma levels within seconds to minutes and declines rapidly. Intravenous administration produces the highest and fastest peak. Despite these differences, all routes converge on the same hepatic metabolic pathway, so urinary BE detection windows are broadly comparable across routes for equivalent total dose.

Hepatic and plasma esterase activity drive cocaine clearance. Cocaine is hydrolyzed by plasma and hepatic carboxylesterases to BE and ecgonine methyl ester. Individuals with reduced pseudocholinesterase activity — whether from genetic variants, liver disease, or pregnancy — metabolize cocaine more slowly, which can extend parent-drug detection in blood and saliva and modestly extend urinary metabolite detection. Co-ingestion of ethanol diverts a portion of the metabolic flux to cocaethylene, which has its own pharmacokinetic profile and is detectable on confirmation testing.

Hydration affects urinary concentration of BE in the same way it affects any urinary analyte. Heavily dilute specimens may fall below the 150 ng/mL screening cutoff even when BE is present, which is why specimen-validity testing (creatinine below 20 mg/dL, specific gravity below 1.003) flags the sample for recollection in federally regulated programs. Renal function changes are less impactful than for renally eliminated opioids, but advanced kidney disease can extend the detection window modestly. Body composition has minimal effect on BE detection because cocaine and BE are not appreciably lipophilic.

SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs set the initial immunoassay cutoff for cocaine metabolite at 150 ng/mL of benzoylecgonine in urine. Specimens that test at or above this level proceed to confirmation by gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC-MS/MS), where the confirmatory cutoff for BE is 100 ng/mL. These thresholds apply to DOT-regulated employers, federal civilian agencies, and federal contractors covered by the Drug-Free Workplace Act.

Non-federal clinical and workplace programs are free to set their own cutoffs and often do. Lower cutoffs (50 ng/mL or even 25 ng/mL) are sometimes used in substance-use-disorder treatment and pain-management settings where greater sensitivity to recent use matters. Higher cutoffs are uncommon for cocaine because the SAMHSA thresholds already balance sensitivity and specificity well. Magenta's CLIA-waived dip cards and integrated cups are calibrated to the SAMHSA 150 ng/mL BE cutoff by default; talk to us about custom cutoffs for specialty applications.

Saliva and hair testing use different thresholds. SAMHSA's oral-fluid guidelines specify an 8 ng/mL initial cutoff and an 8 ng/mL confirmation cutoff for the combined cocaine plus BE analyte panel. Hair testing is not yet a SAMHSA-authorized matrix for federal programs as of this writing; commercial laboratories typically use 500 pg/mg for cocaine on hair with mass-spectrometric confirmation, with the explicit understanding that hair cannot localize use within the 90-day window represented by the sample.

Lateral-flow immunoassay is the standard format for point-of-care cocaine screening. The test strip contains a membrane impregnated with anti-benzoylecgonine antibodies and a colored conjugate. When urine wicks up the strip, free BE from the sample competes with the labeled conjugate for antibody binding sites. If BE is present at or above the device cutoff, it occupies enough antibody binding sites that the conjugate cannot accumulate at the test line, producing the characteristic no-test-line positive result. The control line confirms that reagents are functional. All Magenta dip cards and cups use this format and produce a read in approximately five minutes.

Cocaine immunoassays are exceptionally specific by the standards of point-of-care testing. The benzoylecgonine molecule is structurally distinct from other commonly tested analytes, and routine over-the-counter and prescription medications do not produce false positives. Notably, lidocaine, procaine, tetracaine, and other -caine local anesthetics do NOT cross-react with cocaine immunoassays despite the shared naming convention — the -caine ester or amide structures are not recognized by anti-BE antibodies. This is a frequent source of confusion in clinical settings and worth documenting in MRO and donor-education materials.

The most operationally important source of legitimate positive results outside illicit cocaine use is coca-leaf tea or coca-leaf products, which contain native cocaine and produce real BE in vivo. Coca-leaf products are DEA Schedule II in the United States and unlawful to import or possess, but they are widely sold in parts of South America and have been documented in U.S. travelers' urine for several days after a single cup. Topical or intra-procedural medical use of cocaine hydrochloride for otolaryngologic or ophthalmic anesthesia is rare but does occur and will produce a positive screen; a Medical Review Officer should review confirmed positives against any documented medical exposure.

Confirmation testing by GC/MS or LC-MS/MS is the gold standard for resolving any presumptive positive. These instrumental methods identify benzoylecgonine by its specific mass spectrum and quantify it precisely, and they can additionally quantify parent cocaine, cocaethylene, and ecgonine methyl ester when present. SAMHSA-certified laboratories perform confirmation on every screening positive in federally regulated programs. The presence of cocaethylene on confirmation establishes concurrent cocaine and alcohol use; the presence of parent cocaine alongside BE may indicate more recent use than BE alone.

Specimen validity testing accompanies every workplace cocaine screen. Laboratories and point-of-care devices check creatinine and specific gravity to identify dilute specimens, pH to identify adulteration, and oxidizing-agent panels to identify products marketed to defeat drug tests. Magenta's adulteration-panel cups include creatinine, pH, specific gravity, glutaraldehyde, nitrite, and oxidant pads. A positive adulteration finding generally triggers a refusal-to-test consequence under federal rules, equivalent to a confirmed positive.